Menarini Silicon Biosystems announces publication of the DETECT III trial results highlighting the potential clinical utility of HER2 testing in circulating tumor cells with CELLSEARCH

/PRNewswire/ -- Menarini Silicon Biosystems, a pioneer of liquid biopsy technology, announced today the publication, in the Journal of Clinical Chemistry, of...

Related Keywords

Germany ,China ,United States ,Italy ,Asia Pacific ,Fabio Piazzalunga ,Wolfgang Janni ,Department Of Obstetrics ,Us Food Drug Administration ,University Of Ulm ,China National Medical Products Administration ,Menarini Group ,Research Use ,Circulating Tumor Cells ,Silicon Biosystems ,Clinical Chemistry ,Tyrosine Kinase Inhibitor ,Menarini Silicon Biosystem ,Menarini Silicon ,Circulating Tumor Cell ,Drug Administration ,Metastatic Breast ,Tumor Cell Kit ,Research Use Only ,Huntingdon Valley ,Tumor Phenotyping Reagent ,Menarini Silicon Biosystems ,